SLN Stock - Silence Therapeutics plc
Unlock GoAI Insights for SLN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $43.26M | $25.38M | $21.66M | $12.41M | $5.48M |
| Gross Profit | $31.45M | $15.06M | $8.19M | $4.96M | $1.72M |
| Gross Margin | 72.7% | 59.3% | 37.8% | 39.9% | 31.3% |
| Operating Income | $-63,319,000 | $-49,604,000 | $-61,040,000 | $-45,814,000 | $-35,847,000 |
| Net Income | $-45,309,000 | $-43,267,000 | $-50,334,000 | $-39,410,000 | $-32,547,000 |
| Net Margin | -104.7% | -170.5% | -232.4% | -317.4% | -594.0% |
| EPS | $-2.37 | $-3.48 | $-3.81 | $-1.36 | $-1.12 |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 11th 2025 | Goldman | Initiation | Sell | $6 |
| December 2nd 2024 | BMO Capital Markets | Reiterated | Outperform | - |
| September 3rd 2024 | Jefferies | Initiation | Buy | $40 |
| January 31st 2024 | BMO Capital Markets | Initiation | Outperform | $67 |
| May 8th 2023 | Morgan Stanley | Initiation | Overweight | $20 |
| December 9th 2022 | Morgan Stanley | Initiation | Equal Weight | $18 |
Earnings History & Surprises
SLNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-0.37 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.40 | $-0.45 | -12.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.27 | $-0.54 | -100.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.18 | $-0.60 | -233.3% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | — | $0.13 | — | — |
Q4 2024 | Nov 14, 2024 | $-0.42 | $-0.75 | -78.6% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.23 | $-0.05 | +78.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.56 | $-0.28 | +50.0% | ✓ BEAT |
Q3 2023 | Aug 16, 2023 | $-0.59 | $-0.36 | +39.0% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-0.51 | $-0.35 | +31.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.60 | $-0.25 | +58.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.60 | $-0.16 | +73.1% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.62 | $-0.11 | +81.9% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.62 | $-0.42 | +32.3% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | — | $-0.18 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.13 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.03 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.14 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.09 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.08 | — | — |
Latest News
Silence Therapeutics President And CEO Craig Tooman Steps Down; Chairman Iain Ross Named Interim Leader
📉 NegativeCORRECTION: Silence Therapeutics Q3 EPADS $(0.45) Misses $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate
📉 NegativeSilence Therapeutics Q3 EPS $(0.15) Beats $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate
➖ NeutralSilence Therapeutics Completes Patient Enrollment in Phase 2 Study of Divesiran
📈 PositiveHC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
➖ NeutralFrequently Asked Questions about SLN
What is SLN's current stock price?
What is the analyst price target for SLN?
What sector is Silence Therapeutics plc in?
What is SLN's market cap?
Does SLN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SLN for comparison